Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

Please enter the email address for your account. A verification code will be sent to you. Once you have received the verification code, you will be able to choose a new password for your account.

THERANEXUS presents an update on the progress of its main programs and announces its cash position as of 31 December 2020

18/01/2021
Download PDF File (538Ko)

THERANEXUS, Lyon Neuroscience Research Center and CERMEP announce the creation and funding of new joint public/private laboratory “Neuroimaging for Drug Discovery” (NI2D)

18/12/2020
Download PDF File (428Ko)

The Food And Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by THERANEXUS and BBDF

19/11/2020
Download PDF File (318Ko)

Presentation of the results of the phase 1b clinical study of THN201 for Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease conference (CTAD)

04/11/2020
Download PDF File (605Ko)

THERANEXUS and BBDF obtain European "orphan medicinal product" designation for BBDF-101 in Batten disease

21/10/2020
Download PDF File (290Ko)